T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools
Summary:
The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.
An Anti-Viral Polypeptide: Griffithsin
Summary:
Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Summary:
The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary:
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Summary:
The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.
CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples
Description of Technology:
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities.
SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation
Description of Technology:
The Transforming Growth Factor Beta (TGF-ß) ligands (i.e., TGF-ß1, -ß2, -ß3) are key regulatory proteins in animal physiology. Disruption of normal TGF-ß signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-ß activates TGF-ß receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression and contribute to tumorigenesis. Reliable animal models are essential for the study of TGF-ß signaling.
Immunogens for Use in a High Efficacy HIV Vaccine
Summary:
The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.
Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES
Summary:
NCI is seeking parties to non-exclusively license the ADR-RES cell line.
Description of Technology:
Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.
Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
Description of Technology:
Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells.